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A B S T R A C T
Background: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular and immune
dysfunction. A hallmark of SSc is the excessive accumulation of extracellular matrix in the skin and in
internal organs. There is a high and unmet medical need for novel therapies in this disease. The
pathogenesis of SSc is complex and still poorly understood, but the innate immune system has emerged
as an important factor in the disease. SSc patients show increased numbers of macrophages/monocytes
in the blood and in the skin compared to healthy individuals and these cells are important sources of
proﬁbrotic cytokines and chemokines. Paquinimod belongs to a class of orally active quinoline-3-
carboxamide (quinoline) derivatives with immunomodulatory properties and has shown effects in
several models of autoimmune/inﬂammatory disorders. Paquinimod is currently in clinical development
for treatment of SSc. The immunomodulatory effects of paquinimod is by targeting the myeloid cell
compartment via the S100A9 protein.
Objective: In this study we investigate whether targeting of myeloid cells by paquinimod can effect
disease development in an experimental model of SSc, the tight skin 1 (Tsk-1) mouse model.
Methods: Seven weeks old female B6.Cg-Fbn1Tsk/J (Tsk-1) mice were treated with vehicle or paquinimod
at the dose of 5 or 25 mg/kg/day in the drinking water for 8 weeks. The effect of paquinimod on the level
of skin ﬁbrosis and on different subpopulations within the myeloid cell compartment in skin biopsies
were evaluated by using histology, immunohistochemisty, a hydroxyproline assay and real-time PCR.
Furthermore, the level of IgG in serum from treated animals was also analysed. The statistical analyses
were performed using Mann-Whitney nonparametric two tailed rank test.
Results: The results show that treatment with paquinimod reduces skin ﬁbrosis measured as reduction of
skin thickness and decreased number of myoﬁbroblasts and total hydroxyproline content. The effect on
ﬁbrosis was associated with a polarization of macrophages in the skin from a pro-ﬁbrotic M2 to a
M1 phenotype. Paquinimod treatment also resulted in a reduced TGFb-response in the skin and an
abrogation of the increased auto-antibody production in this SSc model.
Conclusions: Paquinimod reduces skin ﬁbrosis in an experimental model of SSc, and this effect correlates
with local and systemic effects on the immune system.
ã 2016 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Abbreviations: a-SMA, a-smooth-muscle-actin; CCL2, chemokine (C-C motif) ligand 2; CCR2, chemokine receptor 2; Col1a1, collagen 1a1; Col1a2, collagen 1a2; Col3a1,
collagen 3a1; Ctgf, connective tissue growth factor; DAMP, damage-associated molecular pattern; ECM, extracellular matrix; Fn1, ﬁbronectin 1; iNOS, inducible nitric oxid
synthase; IFNs, interferons; MS, multiple sclerosis; RAGE, receptor for advanced glycation end-product; SLE, systemic lupus erythematosus; SSc, Systemic Sclerosis; TGFb,
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Systemic Sclerosis (SSc) is a rare connective tissue disease
characterized by vascular and immune dysfunction, and ﬁbrosis
that damage multiple internal organs such as the gastrointestinal
tract, lungs, heart and kidney [1]. There is no cure for SSc and
existing treatments are focused on controlling symptoms and
preventing complications [2]. Thus, there is a high unmet medical
need for novel therapies in this disease. The pathogenesis of SSc is
complex and still poorly understood, but immunological activity
is suggested to be the key stimulator of ﬁbrosis and vascular
abnormalities. This is supported by observations of high
concentrations of immune mediators such as cytokines and
chemokines, inﬁltration of mononuclear cells in affected organs
and the production of autoantibodies [3]. In recent years, the
importance of the innate immune system in the pathogenesis of
SSc is increasingly recognized [4]. Studies have shown elevated
levels of type I Interferons (IFNs), a key regulator of the innate
immune system, in SSc patients [5,6]. It has also been reported
that SSc patients have increased numbers of macrophages/
monocytes in the blood and in the skin compared to healthy
individuals [7,8]. These cells are important sources of ﬁbrosis-
inducing cytokines like for instance transforming growth factor b
(TGFb). Macrophage-derived TGFb stimulates myoﬁbroblasts to
produce various extracellular matrix (ECM) proteins and inhib-
itors of metalloproteases that are involved in the degradation of
the matrix proteins [9]. Taken together, this suggests that
targeting the innate immune system has the potential to improve
the treatment of SSc.
Paquinimod belongs to a class of quinoline-3-carboxamide
(quinoline) derivatives that contains structurally related, orally
active, low molecular weight compounds [10]. Paquinimod has
immunomodulatory properties and interferes with development
of disease in models for several autoimmune/inﬂammatory
disorders, e.g. multiple sclerosis (MS) [11], systemic lupus
erythematosus (SLE) [12] and atherosclerosis [13]. The immuno-
modulatory effects of paquinimod in these models involve the
innate immune system, speciﬁcally the myeloid cell compartment
and it was recently reported that paquinimod selectively inhibited
recruitment of subsets of myeloid cells into inﬂammatory sites
[14]. The S100A9 protein has been identiﬁed as one target
molecule for paquinimod [15]. S100A9 is involved in both
activation and recruitment of myeloid cells into inﬂammatory
sites [16] and a pro-inﬂammatory role for S100A9 is supported by
elevated levels of S100A9 in several autoimmune/inﬂammatory
diseases, including SSc [17–19]. Extracellular S100A9 acts as a
damage-associated molecular pattern (DAMP) that interacts with a
number of receptors, including toll-like receptor 4 (TLR4) and the
receptor for advanced glycation end-product (RAGE) which are
typical pattern recognition receptors expressed on cells within the
myeloid compartment. Paquinimod binds to S100A9 and disrupts
its binding to these receptors [15].
Since paquinimod, and also other quinoline compounds, have
documented effects on the innate immune system and on
inﬂammation [11,14,20,21], we have explored the possibility of
using paquinimod as a novel treatment of SSc. Recently an open-
label study with paquinimod in progressive SSc patients was
completed (NCT01487551). The main objective of this study was to
measure changes in biomarkers and safety parameters in SSc
patients treated with paquinimod for eight weeks. Effects on
several biomarkers relevant for SSc and the mechanism of
paquinimod were observed and results also showed that
paquinimod was well tolerated by the patients (manuscript in
preparation). In this study we have investigated the effect of
paquinimod in an established experimental model of SSc, the tight
skin 1 (Tsk-1) mouse model. The results show that treatment withpaquinimod reduces skin ﬁbrosis and indicate that the mechanism
is mediated via targeting subsets of monocytes/macrophages.
2. Materials and methods
2.1. Animals and animal care
Seven weeks old female B6.Cg-Fbn1Tsk/J (Tsk-1) mice were
purchased from Jackson laboratories (Bar Harbor, ME). Tsk-1 mice
spontaneously develop skin ﬁbrosis as a result of a partial in-frame
duplication in the ﬁbrillin-1 gene [22]. The mice were kept in a
speciﬁed pathogen-free facility and housed 4–8 mice/cage with
food and water ad lib. All animal experiments were conducted in
accordance with the Ethical Committee on Animal Experiments in
Lund, Sweden (permit no M 27-12).
2.2. Test groups, compound formulation and administration
Six animals were sacriﬁced at the age of 7 weeks to determine
the level of ﬁbrosis in the skin at the start of treatment. Thereafter,
8 animals per group were treated with vehicle (water) or
paquinimod ad lib. at the dose of 5 or 25 mg/kg/day in the
drinking water for 8 weeks.
2.3. Skin biopsies
Skin biopsies were taken from the upper back. Biopsies were
ﬁxed for 6 h in 4% PFA and either dehydrated and embedded in
parafﬁn or soaked in 25% sucrose solution until sinking to the
bottom of the vial, and thereafter frozen in OCT Tissue Tec
(Histolob Products AB, Gothenburg, Sweden). For the analysis of
hydroxyproline content, biopsies were frozen in liquid nitrogen.
For gene expression analysis biopsies were frozen in RNAlater1
(Life Technologies, Carlsbad, CA).
2.4. Histology and immunohistochemistry
Parafﬁn embedded skin biopsies were transversally sectioned
at 4–10 mm and sections collected from 3 different levels (100 mm
between each level). The sections were dried at 37 C overnight and
then processed for histological staining with Mayer Hematoxylin
(Sigma-Aldrich, St Louis, MO) and Erytrosin B (VWR International
Ltd., Poole, UK) or for immunohistochemistry. Thickness of
hypodermis, i.e. the connective tissue layer beneath panniculus
carnosus, was measured in hematoxylin/erytrosin stained sections
at three levels in each biopsy with the value for each level a mean
of three measurements in the section (left, middle and right). The
value for each individual represented as a mean of the three levels
measured.
For detection of myoﬁbroblasts, the sections were incubated
with the primary antibody, alkaline phosphatase conjugated
mouse anti-alpha-smooth-muscle-actin (a-SMA, Sigma-Aldrich,
St Louis, MO), visualized in Permanent red (DakoSweden AB,
Stockholm, Sweden) and mounted in aqueous mounting medium
(DakoSweden AB). Myoﬁbroblasts were measured in three ﬁelds
under 20 objective lens on each section, sections from three
levels were analysed and presented as mm2 stained a SMA area/
length of sample (mm). The value for each individual is
represented as a mean of the three levels measured. The stained
myoﬁbroblasts were manually selected according to location and
morphology to differentiate them from other cell types that also
express a-SMA, such as pericytes and vascular smooth muscle
cells.
For detection of CD206 and F4/80, immunoﬂuorescence was
used on frozen sections (8 mm) according to standard protocols.
The primary antibodies used were rabbit-anti-CD206 (AbCam,
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Isotype antibodies for both anti-CD206 and anti-F4/80 were used
on separate sections as control. The secondary antibodies used
were donkey-anti-rabbit Alexa ﬂuor 488 (Jackson ImmunoRe-
search, West Grove, PA) and Alexa ﬂuor 555 goat-anti-rat (Life
Technologies Invitrogen, Eugene, OR). The slides were mounted in
ProLongGold Antifade Kit including DAPI (Life Technologies
Invitrogen, Eugene, OR). The CD206 stained cells were measured
in a standardized area in hypodermis. The positive stained cells
were expressed as percentage of stained area in relation to total
analyzed area. All morphometric measurements were performed
by using a Leica DMRXE microscope equipped with a digital
camera and a computerized image analysis system (Q500, Leica,
Switzerland).
2.5. Hydroxyproline assay
The amount of hydroxyproline in skin biopsies was analyzed
using a Hydroxyproline Assay Kit (BioVision, San Jose, CA). Each
tissue section was homogenized in 250 mL ultrapure water.
Thereafter, 250 mL concentrated HCl were added and the mixture
was heated at 120 C for 3 h. Subsequently, the hydrolyzed samples
were analysed according to manufacturer’s instructions.
2.6. Gene expression
Total RNA was prepared from skin samples, frozen in RNAlater,
using RNeasy kit (Qiagen, Hilden, Germany). RNA concentrationFig.1. Inhibition of skin ﬁbrosis development by paquinimod treatment. A) Hypodermal t
and vehicle or paquinimod treated Tsk-1 mice (n = 7–8) at 15 weeks of age. B) Representat
of treatment at 8 weeks (II) vehicle treated and (III) treated with paquinimod 5 mg/kg at te
skin biopsies from Tsk-1 mice at start of treatment and after 8 weeks of treatment with p
treatment and after 8 weeks of treatment with paquinimod or vehicle. The graphs shoand purity were determined using a NanoDrop Spectrophotometer
for determing the A260/A280 ratio and an Agilent Bioanalyzer to
further check the RNA quality. cDNA was prepared using two mg
RNA per sample with Qiagen RT2 First strand kit (Qiagen Sciences,
Germantown, MD) according to the manufacturer’s instructions.
Expression levels for mRNA of Col1a2 (RefSeq. NM_007743),
Col3a1 (RefSeq. NM_009930), Ctgf (RefSeq. NM_010217), Fn1
(RefSeq. NM_010233), Il-13 (RefSeq. NM_008355) and Thbs1
(RefSeq. NM_011580), with references beta-actin (Actb) (RefSeq.
NM_007393) and beta-2 microglobulin (B2m) (RefSeq.
NM_009735), were determined using a customized array of
validated RT2 qPCR Primer Assays (Qiagen Sciences). Additional
RT2 qPCR Primer Assays used were Ccr2 (RefSeq. NM_009915.2)
and reference Actb (RefSeq. NM_007393.3) purchased from
(Qiagen Sciences). Real-time qPCR was carried out on a Thermo-
cycler CFX96 instrument (Bio-Rad, CA) using RT2 SYBR Green
Mastermix (Qiagen Sciences) according to the manufacturer’s
instruction. Expression levels of Cd206 and Arg-1 were determined
on the same instrument using SsoFastTM EvaGreen1 Supermix
(Bio-Rad Laboratories, Singapore). The sequences of the
Cd206 primers were 50-GCA AAT GGA GCC GTC TGT GC-30
(forward), 50-CTC GTG GAT CTC CGT GAC AC-30 (reverse), Arg-
1 primers were 50-GTG AAG AAC CCA CGG TCT GT-30 (forward) and
50-CTG GTT GTC AGG GGA GTG TT-30 (reverse), Il-12b primers were
50-GTG TGG ATC CAA AGC AAT AC-30 (forward) and 50-GTC TGC TCA
TTC ATG ACA AG-30 (reverse), iNOS (Nos2) primers were 50-TGG
TGG TGA CAA GCA CAT TT-30 (forward) and 50-AAG GCC AAA CAC
AGC ATA CC-30 (reverse), beta-actin primers were 50-CCC ACA CTGhickness in skin biopsies from Tsk-1 mice at 7 weeks of age (start of treatment; n = 6)
ive histological sections showing hypodermal thickness in the skin biopsies. (I) start
rmination of the study. Scale bar representing 200 mm. C) Hydroxyproline content in
aquinimod or vehicle. D) Myoﬁbroblasts in skin biopsies from Tsk-1 mice at start of
w individual values and the horizontal line represents median value.
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30 (reverse), B2m primers were 50-ATT CAC CCC CAC TGA GAC TG-30
(forward) and 50-TGC TAT TTC TTT CTG CGT GC-30 (reverse), all
purchased as custom primers (Life Technologies Invitrogen, CA).
The mRNA for Col1a1 (RefSeq. NM_007742) was determined using
Quantitect Primer Assay with QuantiFast SYBR Green PCR kit
(Qiagen).
Fold changes in mRNA expression of the genes were calculated
by using the DDCq method. The relative normalized expression of
each gene for each sample was calculated as (2^ (DCq)) divided
(2^ (DCq,average,control)), where the vehicle treated mice is the
control group.
2.7. Serum IgG level
Serum samples were collected at termination. The level of
serum total IgG was analysed using an IgG mouse ELISA kitFig. 2. Effects on the myeloid cell compartment. A) Changes of mRNA levels relative vehic
genes after 8 weeks of treatment (n = 8) with 25 mg/kg paquinimod. Graph shows m
CD206 staining of a standardized area in skin sections from start of treatment and vehicl
double staining with anti-CD206 (green) and anti-F4/80 (red) antibodies, the upper right
(D) Change in mRNA levels relative vehicle treatment (n = 8) of Ccr2 at start of treatmen
plots and the horizontal line represents median value.(Abnova, Heidelberg, Germany), according to the manufacturer’s
instructions.
2.8. Statistical analysis
Statistical analyses was performed using Mann-Whitney
nonparametric two tailed rank test (alpha = 0.05) by GraphPad
Prism 4 software. P values <0.05 were considered to be statistically
signiﬁcant.
3. Results
3.1. Paquinimod reduces skin ﬁbrosis in the Tsk-1 model
Skin ﬁbrosis in Tsk-1 mice is manifested by an increased
production of collagen by myoﬁbroblasts located in the skin,
starting from week one after birth and the ﬁbrosis graduallyle treatment (n = 8) of M2- (Arg-1, Il-13, Cd206) and M1-associated (Il-12b and iNos)
ean  SEM. B) CD206 immunoﬂuorescence in hypodermis presented as percent
e or paquinimod treated mice. Graph shows mean  SEM. C) Immunohistochemical
 image shows a magniﬁcation of a double stained cell. Scale bar represents 100 mm.
t (n = 6) and at 8 weeks of treatment (n = 8) with paquinimod. The graphs show box
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25 mg/kg/day was administered ad lib in the drinking water from
week 7 to week 15. To mimic a clinical situation the treatment
started at a time point when ﬁbrosis already was established in the
hypodermis. The ﬁbrosis in the hypodermal layer of the skin was
measured as an increase in the hypodermal thickness and collagen
content. Fig. 1A and B show a clear increase in hypodermal
thickness in 15-week old mice treated with vehicle compared to 7-
week old mice (start of treatment). Hypodermal thickness was
reduced by 24% (p = 0.038) in animals treated with 5 mg/kg
paquinimod and by 16% (p = 0.231) in animals treated with 25 mg/
kg compared to vehicle treated mice. Deposition of collagen,
quantiﬁed by measuring the level of hydroxyproline, also increased
in the skin as the disease developed from week 7 to week 15. A
signiﬁcant reduction of the hydroxyproline content was recorded
after treatment with the highest dose of paquinimod (22%
p = 0.028) (Fig. 1C). The main producers of collagen in SSc are
the myoﬁbroblasts and this cell population increases in number in
the skin of Tsk-1 mice during disease development. An increase of
34% (p = 0.008) from week 7 to week 15 was recorded (Fig. 1D).
After 8 weeks of treatment with 25 mg/kg paquinimod the number
of myoﬁbroblasts in the skin was signiﬁcantly reduced (20%,
p = 0.014) compared to vehicle treated animals (Fig. 1D). Altogeth-
er, these data support that paquinimod has anti-ﬁbrotic effects in
the skin of Tsk-1 mice.Fig. 3. Change in mRNA expression of different TGFb-responsive genes. A–D) Change in 
ﬁbronectin 1 (Fn1), trombospondin 1 (Thbs1) and Collagen 1a2 (Col1a2) at start of trea
graphs show box plots and the horizontal line represents median value.3.2. Paquinimod targets myeloid subsets in the skin of Tsk-1 mice
It has previously been reported that the number of myeloid cells
is increased in ﬁbrotic tissue in SSc [8] and that these cells play an
important role in ﬁbrosis [23]. In order to elucidate whether the
observed anti-ﬁbrotic effects by paquinimod treatment are
mediated by modulation of the myeloid cells, CD11b+ cells were
quantiﬁed in skin biopsies from the Tsk-1 mice by immunohis-
tochemistry. An increased number of CD11b+ cells was observed in
the skin during disease progression, but no effect on this cell
population was evident by treatment (data not shown). To
investigate if paquinimod affects subsets within the very
heterogeneous CD11b+ cell population, real-time RT-PCR analysis
was used to detect speciﬁc myeloid cell markers. First, markers
associated with the pro-ﬁbrotic M2 macrophages were investigat-
ed, i.e. IL13, Arginase-1 (Arg-1) and the mannose receptor C, type 1
(CD206). A down-regulation of these M2 markers was observed in
mice treated with 25 mg/kg paquinimod compared to vehicle
treated animals, although the effect on CD206 did not reach
statistical signiﬁcance. The down-regulation of M2-associated
genes was accompanied by an increase of mRNA levels of IL12b
and inducible nitric oxid synthase (iNOS), both expressed by M1-
macrophages, Fig. 2A. This suggests that paquinimod induces a
polarization of macrophages from a pro-ﬁbrotic M2 to an anti-
ﬁbrotic M1 phenotype in Tsk-1 mice. Immunohistochemicalgene expression relative vehicle treatment of connective tissue growth factor (Ctgf),
tment (n = 6) and at 8 weeks of treatment with paquinimod or vehicle (n = 8). The
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skin in paquinimod treated animals (Fig. 2B). The majority of the
CD206+ cells expressed the macrophage marker F4/80 (Fig. 2C),
further strengthening the notion that paquinimod treatment
targets the M2 macrophages in this model. Finally, a 54% (p =
0.0019) reduction of mRNA levels for the chemokine receptor 2
(CCR2), a receptor mainly expressed on inﬂammatory monocytes
that are implicated in the development of ﬁbrosis, was observed in
mice treated with 25 mg/kg paquinimod compared to vehicle
treated animals (Fig. 2D) [24].
3.3. Paquinimod reduces the expression of TGFb regulated genes
One of the major pro-ﬁbrotic cytokines produced by
M2 macrophages is TGFb and up-regulation of the TGFb signalling
axis in Tsk-1 mice has been described [25]. Therefore, to further
study the effect of paquinimod, the expression of a number of
TGFb-responsive genes in the skin was analysed by real-time RT-
PCR. Fig. 3A–C shows that paquinimod reduces the mRNA levels of
connective tissue growth factor (Ctgf), ﬁbronectin 1 (Fn1) and
trombospondin 1 (Thbs1). Also a trend towards a reduction of
collagen 1a2 (Col1a2) (Fig. 3D), Col1a1 and Col3a1 (data not
shown) was recorded. Altogether, this indicates a reduced TGFb
response locally after paquinimod treatment, and this is in line
with an effect on TGFb-producing myeloid cells in the skin.
3.4. Paquinimod reduces the level of total IgG in serum
Similarly to SSc in humans, an increase of circulating auto-
antibodies has been described in Tsk-1 mice [3,26]. In this study a
doubling in level of total IgG in serum was recorded during disease
development from week 7 to week 15 (Fig. 4). This may reﬂect the
development of auto-antibodies against speciﬁc antigens in these
mice. In both dose groups a signiﬁcant reduction of circulating IgG
was observed during disease development of Tsk-1 mice. The Ig G
levels in paquinimod treated animals were comparable with the
levels observed in 7 weeks old mice (start of treatment) (Fig. 4).
4. Discussion
Skin ﬁbrosis is considered a hallmark of SSc. In this paper we
have investigated the effect of paquinimod on skin ﬁbrosis in a
spontaneous SSc model, the Tsk-1 mice. Paquinimod is an
immunomodulatory agent with ameliorating effect in animal
models for several different autoimmune and inﬂammatoryFig. 4. The effects of paquinimod treatment on the total IgG level in serum from Tsk-
1 mice at start of treatment (n = 6) and after 8 weeks of treatment with paquinimod
or vehicle (n = 8). The graph shows individual values and the horizontal line
represents median value.disorders. It has been evaluated in clinical Phase 1 studies in
healthy subjects, systemic lupus erythematosus (SLE) and SSc
patients and was well tolerated at dose levels predicted, from
preclinical data, to be efﬁcacious [11–13]. Paquinimod binds to
S100A9 and inhibits its binding to the pro-inﬂammatory receptors
RAGE and TLR4 [15]. S100A9 may be directly involved in the
ﬁbrotic events occurring in SSc patients as S100A9 has been shown
to stimulate proliferation and production of collagen by ﬁbroblasts
via binding to RAGE [19,27], but an indirect role where
S100A9 affects innate immunity in the skin is however also
possible. For example, mice lacking S100A9 have an impaired
recruitment of myeloid cells to a wound, resulting in faster wound
closure and less scar tissue formation [28]. In line with this,
paquinimod has previously been shown to interfere with the
recruitment and accumulation of myeloid cells into inﬂammatory
sites [14,20].
Based on the previously documented effects of paquinimod on
S100A9 and innate immunity we reasoned that paquinimod may
be an option in the treatment of SSc. In this study we show, for the
ﬁrst time, that paquinimod has signiﬁcant effects on skin ﬁbrosis in
Tsk-1 mice and that this effect correlates with local and systemic
effects on the immune system. Anti-ﬁbrotic effects could be
detected in the skin both as a reduction of hypodermal thickness
and as a reduction of the collagen content in the skin. The
treatment also signiﬁcantly reduced the number of collagen-
producing myoﬁbroblasts. The amplitude of the reduction of
myoﬁbroblasts did, however, not fully correlate to the reduction of
hypodermal thickness at 5 mg/kg, which was more pronounced.
The dermal thickness, is a read-out for ﬁbrosis that reﬂects a
balance between production and degradation of extracellular
matrix components, which could explain the differences in
response of paquinimod on myoﬁbroblasts count and hypodermal
thickness in the same dose group. Myoﬁbroblasts differentiate
from ﬁbroblasts in response to signals derived from myeloid cells
[4]. Effects on myeloid cells were evident by real-time RT-PCR
analysis of skin biopsies. First, treatment with paquinimod
signiﬁcantly reduces the mRNA levels for CCR2. CCR2 is a
chemokine receptor expressed primarily on inﬂammatory mono-
cytes [24]. A role for CCR2 in the pathogenesis of SSc is supported
by the fact that high levels of CCR2 are found in skin biopsy
samples from patients of early-stage diffuse cutaneous SSc [29].
Also, mice lacking CCR2 display impaired mononuclear cell
recruitment to sites of inﬂammation [30] and are resistant to
experimental ﬁbrosis [31]. Given the documented effects of
paquinimod on inﬁltration of myeloid cells, it is likely that the
reduced expression of CCR2 represents a reduction of this cell
population as a result of paquinimod treatment in the Tsk-1 mice.
However, CCR2 may also be expressed on other cells, e.g. T cells,
ﬁbroblasts and ﬁbrocytes that are also involved in the ﬁbrotic
events and it cannot be ruled out from our results that the
reduction also includes these cells. The effect of paquinimod on
CCR2 expression was also observed in a clinical open-label study in
SSc patients (NCT01487551; manuscript in preparation), showing
that CCR2 may qualify as a pharmacodynamic biomarker for
paquinimod in future clinical trials in SSc patients.
The chemokine (CC motif) ligand 2 (CCL2)-CCR2 axis has been
described to be involved in the polarization of macrophages
towards a M2 phenotype [32]. These pro-ﬁbrotic M2 macrophages
express the mannose receptor CD206 and Arg-1, the latter being
directly involved in the synthesis of collagen [33]. Interestingly,
paquinimod treated mice had reduced mRNA levels of both
CD206 and Arg-1, as well as a reduction of CD206 expressing cells
in the skin suggesting a reduction of M2 macrophages. Also, mRNA
levels of the M2-inducing cytokine IL-13 were signiﬁcantly
reduced by paquinimod treatment. The reduction of M2 markers
was accompanied by an increase of mRNA levels for IL-12b and
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M1 macrophages. These results support that paquinimod induces
a shift from pro-ﬁbrotic M2 macrophages to a M1 phenotype in the
skin of Tsk-1 mice. There are remarkable similarities between the
molecular processes in wound healing and cancer, and tumors are
sometime referred to as a never healing wound. It is interesting to
note that the ﬁbrotic skin in SSc or Tsk-1 mice in fact share some
similarities with the microenvironment found in tumors that is to a
large part regulated by myeloid cells. In the tumor, these cells
appear as tumor-associated M2 macrophages or inﬁltrating
monocytic/granulocytic cells. Recent studies with tasquinimod,
another quinoline compound, showed that tasquinimod triggers a
polarization of macrophages from a M2 to a M1 phenotype in the
tumour microenvironment [34,35].
In ﬁbrotic tissue the M2 macrophages are the major producers
of ﬁbrotic cytokines and growth factors such as TGFb [36]. In this
study we observed down regulation of mRNAs for several TGFb
regulated genes such as Ctgf, Thbs1, Fn1 and Col1a2, which all are
involved in the development of ﬁbrosis. The involvement of Ctgf
and Col1a2 in ﬁbrosis in this mouse model is supported by the fact
that they have earlier shown a higher level of mRNA in Tsk-
1 compared to wild type littermates [37,38]. In Fig. 3C an increase
of Thbs1 was recorded from start of treatment to week 15 in vehicle
treated animals, indicating involvement of also this gene in the
development of ﬁbrosis in these mice. The observed disruption of
the TGFb signalling pathway in this study could be explained by
paquinimod targeting of the M2 population. This paper has focused
on local changes of the myeloid cell compartment within the
ﬁbrotic tissue. However, the possibility that a systemic effect from
oral treatment of paquinimod on myeloid cells, e.g. the M1 and
M2 macrophages, could contribute the observed reduction of
ﬁbrosis in this study can of course not be ruled out.
Paquinimod has previously been shown to reduce the level of
circulating auto-antibodies and total IgG in an experimental model
for SLE [12]. Similar to SSc patients, Tsk-1 mice also develop auto-
antibodies [3,26] that are mainly speciﬁc for nuclear proteins
associated with necrotic tissue damage. An increase in total IgG
serum levels were observed as the disease progressed and this
probably represented an increase of speciﬁc auto-antibodies. We
observed that paquinimod treatment effectively inhibits the
increase of total IgG in the serum. The effect of paquinimod on
a B cell response and antibody production has earlier been
reported to be restricted to the primary B cell response, while
treated mice showed normal antibody production in a secondary
antigen recall response [39]. In the situation of autoimmunity, the
autoantibody response can be considered a secondary B cells
response. Therefore, the observed reduction of serum IgG in the
Tsk-1 model might be a consequence of the decrease in the ﬁbrosis
in treated mice rather than a direct effect on B cell activation and
antibody production.
In summary, we show that paquinimod reduces the develop-
ment of ﬁbrosis in an experimental model of SSc when starting
treatment at 7 weeks of age with already established ﬁbrosis in the
hypodermis. Paquinimod treatment leads to down regulation of
genes that have been shown to be important in the pathogenesis of
SSc, ﬁbrosis and myeloid cell action. We postulate that paquinimod
targets the myeloid cell compartment in the ﬁbrotic skin of the Tsk-
1 mice and thereby reduces the pro-ﬁbrotic myeloid M2 response.
These results suggest that immunomodulation by paquinimod
may provide an opportunity for a novel therapy of SSc.
Conﬂict of interests
MS, HCN, MT, DL, BS, HT, HE and TL are employees and
shareholders in Active Biotech.Authors’ contributions
MS contributed to study design, data analyses, and manuscript
preparation. HCN contributed to data analyses, and manuscript
preparation. MT contributed to study design, data analyses, and
manuscript preparation. DL contributed to manuscript prepara-
tion. BS contributed to manuscript preparation. HT contributed to
manuscript preparation. HE contributed to study design, data
analyses, and manuscript preparation. TL contributed to manu-
script preparation. All authors read and approved the ﬁnal
manuscript.
Acknowledgement
This work was partly funded by grants from the Swedish Cancer
Foundation to TL.
References
[1] A. Gabrielli, E.V. Avvedimento, T. Krieg, Scleroderma, N. Engl. J. Med. 360
(2009) 1989–2003.
[2] N. Iwamoto, O. Distler, Molecular targets for therapy in systemic sclerosis,
Fibrogenes. Tissue Repair 5 (2012) S19 (Proceedings of Fibroproliferative
disorders: from biochemical analysis to targeted therapiesPetro E Petrides and
David Brenner).
[3] Y. Hamaguchi, Autoantibody proﬁles in systemic sclerosis: predictive value for
clinical evaluation and prognosis, J. Dermatol. 37 (2010) 42–53.
[4] S. O’Reilly, Innate immunity in systemic sclerosis pathogenesis, Clin. Sci. 126
(2014) 329–337.
[5] B.W. Higgs, Z. Liu, B. White, W. Zhu, W.I. White, C. Morehouse, P. Brohawn, P.A.
Kiener, L. Richman, D. Fiorentino, S.A. Greenberg, B. Jallal, Y. Yao, Patients with
systemic lupus erythematosus, myositis, rheumatoid arthritis and
scleroderma share activation of a common type I interferon pathway, Ann.
Rheum. Dis. 70 (2011) 2029–2036.
[6] D.M. Wuttge, C. Lood, E. Tufvesson, A. Scheja, L. Truedsson, A.A. Bengtsson, R.
Hesselstrand, Increased serum type I interferon activity in early systemic
sclerosis patients is associated with antibodies against Sjogren’s syndrome
antigens and nuclear ribonucleoprotein antigens, Scand. J. Rheumatol. 42
(2013) 235–240.
[7] N. Higashi-Kuwata, M. Jinnin, T. Makino, S. Fukushima, Y. Inoue, F.C.
Muchemwa, Y. Yonemura, Y. Komohara, M. Takeya, H. Mitsuya, H. Ihn,
Characterization of monocyte/macrophage subsets in the skin and peripheral
blood derived from patients with systemic sclerosis, Arthr. Res. Ther. 12 (2010)
R128.
[8] O. Ishikawa, H. Ishikawa, Macrophage inﬁltration in the skin of patients with
systemic sclerosis, J. Rheumatol. 19 (1992) 1202–1206.
[9] P.J. Murray, T.A. Wynn, Protective and pathogenic functions of macrophage
subsets, Nat. Rev. Immunol. 11 (2011) 723–737.
[10] S. Jonsson, G. Andersson, T. Fex, T. Fristedt, G. Hedlund, K. Jansson, L. Abramo, I.
Fritzson, O. Pekarski, A. Runstrom, H. Sandin, I. Thuvesson, A. Bjork, Synthesis
and biological evaluation of new 1 2-dihydro-4-hydroxy-2-oxo-3-
quinolinecarboxamides for treatment of autoimmune disorders: structure-
activity relationship, J. Med. Chem. 47 (2004) 2075–2088.
[11] S. Helmersson, A. Sundstedt, A. Deronic, T. Leanderson, F. Ivars, Amelioration of
experimental autoimmune encephalomyelitis by the quinoline-3-
carboxamide paquinimod: reduced priming of proinﬂammatory effector CD4
(+) T cells, Am. J. Pathol. 182 (2013) 1671–1680.
[12] A.A. Bengtsson, G. Sturfelt, C. Lood, L. Ronnblom, R.F. van Vollenhoven, B.
Axelsson, B. Sparre, H. Tuvesson, M.W. Ohman, T. Leanderson,
Pharmacokinetics, tolerability, and preliminary efﬁcacy of paquinimod (ABR-
215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone
mice and a multicenter, randomized, double-blind, placebo-controlled,
repeat-dose, dose-ranging study in patients with systemic lupus
erythematosus, Arthr. Rheum. 64 (2012) 1579–1588.
[13] L. Yan, P. Bjork, R. Butuc, J. Gawdzik, J. Earley, G. Kim, M.A. Hofmann Bowman,
Beneﬁcial effects of quinoline-3-carboxamide (ABR-215757) on
atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice,
Atherosclerosis 228 (2013) 69–79.
[14] A. Deronic, S. Helmersson, T. Leanderson, F. Ivars, The quinoline-3-
carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment
during sterile inﬂammation: leukocyte- and context-speciﬁc effects, Int.
Immunopharmacol. 18 (2014) 290–297.
[15] P. Bjork, A. Bjork, T. Vogl, M. Stenstrom, D. Liberg, A. Olsson, J. Roth, F. Ivars, T.
Leanderson, Identiﬁcation of human S100A9 as a novel target for treatment of
autoimmune disease via binding to quinoline-3-carboxamides, PLoS Biol. 7
(2009) e97.
[16] C. Kerkhoff, A. Voss, T.E. Scholzen, M.M. Averill, K.S. Zanker, K.E. Bornfeldt,
Novel insights into the role of S100A8/A9 in skin biology, Exp. Dermatol. 21
(2012) 822–826.
M. Stenström et al. / Journal of Dermatological Science 83 (2016) 52–59 59[17] D. Foell, M. Frosch, C. Sorg, J. Roth, Phagocyte-speciﬁc calcium-binding S100
proteins as clinical laboratory markers of inﬂammation, Clin. Chim. Acta; Int. J.
Clin. Chem. 344 (2004) 37–51.
[18] J. Nikitorowicz-Buniak, X. Shiwen, C.P. Denton, D. Abraham, R. Stratton,
Abnormally differentiating keratinocytes in the epidermis of systemic
sclerosis patients show enhanced secretion of CCN2 and S100A9, J. Invest.
Dermatol. 134 (2014) 2693–2702.
[19] X. Xu, W.Y. Wu, W.Z. Tu, H.Y. Chu, X.X. Zhu, M.R. Liang, Y. Xue, J.C. Wang, H.J.
Zou, Increased expression of S100A8 and S100A9 in patients with diffuse
cutaneous systemic sclerosis. A correlation with organ involvement and
immunological abnormalities, Clin. Rheumatol. 32 (2013) 1501–1510.
[20] S. Helmersson, M. Stenstrom, T. Leanderson, F. Ivars, Speciﬁc effect of
immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF
stimulated bone marrow cell cultures: block of initiation of proliferation of Gr-
1+ cells, Int. Immunopharmacol. 11 (2011) 1045–1051.
[21] U. Schulze-Topphoff, A. Shetty, M. Varrin-Doyer, N. Molnarﬁ, S.A. Sagan, R.A.
Sobel, P.A. Nelson, S.S. Zamvil, Laquinimod, a quinoline-3-carboxamide,
induces type II myeloid cells that modulate central nervous system
autoimmunity, PLoS One 7 (2012) e33797.
[22] T. Yamamoto, Animal model of systemic sclerosis, J. Dermatol. 37 (2010) 26–41.
[23] T.A. Wynn, L. Barron, Macrophages: master regulators of inﬂammation and
ﬁbrosis, Semin. Liver Dis. 30 (2010) 245–257.
[24] M. Mack, J. Cihak, C. Simonis, B. Luckow, A.E. Proudfoot, J. Plachy, H. Bruhl, M.
Frink, H.J. Anders, V. Vielhauer, J. Pﬁrstinger, M. Stangassinger, D. Schlondorff,
Expression and characterization of the chemokine receptors CCR2 and CCR5 in
mice, J. Immunol. (Baltimore, Md.: 1950) 166 (2001) 4697–4704.
[25] C. Beyer, G. Schett, O. Distler, J.H. Distler, Animal models of systemic sclerosis:
prospects and limitations, Arthr. Rheum. 62 (2010) 2831–2844.
[26] M. Fujimoto, Y. Hamaguchi, N. Yazawa, K. Komura, K. Takehara, S. Sato,
Autoantibodies to a collagen-speciﬁc molecular chaperone, heat-shock
protein 47, in systemic sclerosis, Clin. Exp. Immunol. 138 (2004) 534–539.
[27] F. Shibata, K. Miyama, F. Shinoda, J. Mizumoto, K. Takano, H. Nakagawa,
Fibroblast growth-stimulating activity of S100A9 (MRP-14), Eur. J. Biochem./
FEBS 271 (2004) 2137–2143.
[28] T. Vogl, S. Ludwig, M. Goebeler, A. Strey, I.S. Thorey, R. Reichelt, D. Foell, V.
Gerke, M.P. Manitz, W. Nacken, S. Werner, C. Sorg, J. Roth, MRP8 and MRP14
control microtubule reorganization during transendothelial migration of
phagocytes, Blood 104 (2004) 4260–4268.
[29] M.T. Carulli, V.H. Ong, M. Ponticos, X. Shiwen, D.J. Abraham, C.M. Black, C.P.
Denton, Chemokine receptor CCR2 expression by systemic sclerosis
ﬁbroblasts: evidence for autocrine regulation of myoﬁbroblast differentiation,
Arthr. Rheum. 52 (2005) 3772–3782.[30] W.A. Kuziel, S.J. Morgan, T.C. Dawson, S. Grifﬁn, O. Smithies, K. Ley, N. Maeda,
Severe reduction in leukocyte adhesion and monocyte extravasation in mice
deﬁcient in CC chemokine receptor 2, Proc. Natl. Acad. Sci. U. S. A. 94 (1997)
12053–12058.
[31] B.B. Moore, R. Paine 3rd, P.J. Christensen, T.A. Moore, S. Sitterding, R. Ngan, C.A.
Wilke, W.A. Kuziel, G.B. Toews, Protection from pulmonary ﬁbrosis in the
absence of CCR2 signaling, J. Immunol. (Baltimore, Md.: 1950) 167 (2001)
4368–4377.
[32] E. Sierra-Filardi, C. Nieto, A. Dominguez-Soto, R. Barroso, P. Sanchez-Mateos, A.
Puig-Kroger, M. Lopez-Bravo, J. Joven, C. Ardavin, J.L. Rodriguez-Fernandez, C.
Sanchez-Torres, M. Mellado, A.L. Corbi, CCL2 shapes macrophage polarization
by GM-CSF and M-CSF: identiﬁcation of CCL2/CCR2-dependent gene
expression proﬁle, J. Immunol. (Baltimore, Md.: 1950) 192 (2014) 3858–3867.
[33] M. Endo, S. Oyadomari, Y. Terasaki, M. Takeya, M. Suga, M. Mori, T. Gotoh,
Induction of arginase I and II in bleomycin-induced ﬁbrosis of mouse lung, Am.
J. Physiol. Lung Cell. Mol. Physiol. 285 (2003) L313–21.
[34] A. Olsson, J. Nakhle, A. Sundstedt, P. Plas, A.L. Bauchet, V. Pierron, L. Bruetschy,
A. Deronic, M. Torngren, D. Liberg, F. Schmidlin, T. Leanderson, Tasquinimod
triggers an early change in the polarization of tumor associated macrophages
in the tumor microenvironment, J. Immunother. Cancer 3 (2015) 53.
[35] L. Shen, A. Sundstedt, M. Ciesielski, K.M. Miles, M. Celander, R. Adelaiye, A.
Orillion, E. Ciamporcero, S. Ramakrishnan, L. Ellis, R. Fenstermaker, S.I. Abrams,
H. Eriksson, T. Leanderson, A. Olsson, R. Pili, Tasquinimod modulates
suppressive myeloid cells and enhances cancer immunotherapies in murine
models, Cancer Immunol. Res. 3 (2015) 136–148.
[36] L.L. McCormick, Y. Zhang, E. Tootell, A.C. Gilliam, Anti-TGF-beta treatment
prevents skin and lung ﬁbrosis in murine sclerodermatous graft-versus-host
disease: a model for human scleroderma, J. Immunol. (Baltimore, Md.: 1950)
163 (1999) 5693–5699.
[37] Y. Matsushita, M. Hasegawa, T. Matsushita, M. Fujimoto, M. Horikawa, T. Fujita,
A. Kawasuji, F. Ogawa, D.A. Steeber, T.F. Tedder, K. Takehara, S. Sato,
Intercellular adhesion molecule-1 deﬁciency attenuates the development of
skin ﬁbrosis in tight-skin mice, J. Immunol. (Baltimore, Md.: 1950) 179 (2007)
698–707.
[38] S. Weingartner, P. Zerr, M. Tomcik, K. Palumbo-Zerr, A. Distler, C. Dees, C. Beyer,
S.L. Shankar, D. Cedzik, P.H. Schafer, O. Distler, G. Schett, J.H. Distler,
Pomalidomide is effective for prevention and treatment of experimental skin
ﬁbrosis, Ann. Rheum. Dis. 71 (2012) 1895–1899.
[39] E. Kallberg, F. Ivars, T. Leanderson, Quinoline-3-carboxamides modulate
primary T cell-dependent B cell responses but do not inhibit functional
immunity, Scand. J. Immunol. 79 (2014) 237–243.
